NCCN临床实践指南：儿童霍奇金淋巴瘤(2022.V1) 戳我得7天指南VIP

发布日期：2022-04-08英文(wén)标题：NCCN Clinical Practice Guidelines in Oncology: Pediatric  Hodgkin Lymphoma (Version1.2022)制定者：美國(guó)國(guó)家综合癌症网络(NCCN,National Comprehensive  Cancer Network)出处：NCCN官网

指南下载：

NCCN临床实践指南：儿童霍奇金淋巴瘤（2022.V1）.pdf

内容介绍：

1.指南来源(Guide Source):

NCCN临床实践指南:儿童霍奇金淋巴瘤  V1.2022.发布已获NCCN肿瘤學(xué)临床实践指南(NCCN指南®)许可(kě)。©2022美國(guó)國(guó)家综合癌症网络公司.保留所有(yǒu)权利。未经NCCN明确的书面许可(kě)，不得出于任何目的以任何形式复制NCCN指南®和文(wén)中的插图。要查看NCCN指南的最新(xīn)完整版本，请访问NCCN.org。NCCN指南是一项持续进行的工作，可(kě)能(néng)会随着新(xīn)的重要数据的出现而不断完善。

2.免责声明(Disclaimers)：

NCCN对其内容、使用(yòng)或应用(yòng)不做任何形式的担保，并否认以任何方式对其应用(yòng)或使用(yòng)承担任何责任。

在下载本篇指南前，请先您详细阅读并同意以下协议：

NCCN内容不得用(yòng)于商(shāng)业目的，以及NCCN作為(wèi)NCCN内容的许可(kě)方，不作任何陈述或保证，并明确否认NCCN指南适用(yòng)于任何特定患者的护理(lǐ)或治疗，任何医院、寻求使用(yòng)《NCCN指南》治疗患者的临床医生或其他(tā)医疗服務(wù)提供者(“提供者”)应根据特定患者护理(lǐ)或治疗的具體(tǐ)临床情况做出独立的医疗判断，NCCN不建议、推荐或认可(kě)任何提供者(无论是否与被许可(kě)方相关)进行任何有(yǒu)偿或无偿的医疗治疗、咨询或服務(wù)，也不应因被许可(kě)方建议、推荐或认可(kě)任何此类提供者的作為(wèi)或不作為(wèi)而直接或间接承担责任。详见《NCCN最终用(yòng)户许可(kě)协议》

3.专家名单(Staff)：

*Jamie E. Flerlage, MD, MS/Chair €St. Jude Children's Research Hospital/The  University of Tennessee Health Science Center

*Susan M. Hiniker, MD/Vice Chair §Stanford Cancer Institute

Saro Armenian, DO, MPH € ‡City of Hope National Medical Center

Adam J. Bobbey, MD фThe Ohio State University Comprehensive Cancer Center -  James Cancer Hospital and Solove Research Institute

Vivian Chang, MD €UCLA Jonsson Comprehensive Cancer Center

Stacy Cooper, MD ‡The Sidney Kimmel Comprehensive Cancer Center at Johns  Hopkins

Don W. Coulter, MD €Fred & Pamela Buffett Cancer Center

Branko Cuglievan, MD €The University of Texas MD Anderson Cancer Center

Kenneth DeSantes, MD €, xUniversity of Wisconsin Carbone Cancer Center

Anusha Preethi Ganesan, MD, PhD ‡Rady Children's Hospital of San Diego/UC San  Diego Moores Cancer Center

Bradford S. Hoppe, MD, MPH §Mayo Clinic Cancer Center

Leidy Isenalumhe, MD, MS € ‡Moffitt Cancer Center

Kara Kelly, MD €Roswell Park Comprehensive Cancer Center

Leslie Kersun, MD, MSCE, MSEd € ‡Children's Hospital of Philadelphia/Abramson  Cancer Center at the University of Pennsylvania

Adam J. Lamble, MD €Fred Hutchinson Cancer Research Center/Seattle Cancer  Care Alliance

Nicole A. Larrier, MD, MSc §Duke Cancer Institute

Sandra Luna-Fineman, MD €University of Colorado Cancer Center

Jeffrey Magee, MD, PhD € ‡Siteman Cancer Center at BarnesJewish Hospital and  WashingtonUniversity School of Medicine

Kwadwo Oduro, MD, PhD ≠ ‡Case Comprehensive Cancer Center/University  Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer  Institute

Martha Pacheco, MD €UT Southwestern SimmonsComprehensive Cancer Center

Arun Ranjan Panigrahi, MD € ‡UC Davis Comprehensive Cancer Center

Anita P. Price, MD фMemorial Sloan Kettering Cancer Center

Kenneth B. Roberts, MD §Yale Cancer Center/Smilow Cancer Hospital

Christine M. Smith, MD € ‡Vanderbilt-Ingram Cancer Center

Aliyah R. Sohani, MD ≠Masschusetts General Hospital Cancer Center

Emily Walling, MD, MPHS €University of Michigan Rogel Cancer Center

Jane N. Winter, MD ‡Robert H. Lurie Comprehensive Cancer Center of  Northwester University

Ana C. Xavier, MD €O'Neal Comprehensive Cancer Center at UAB

4.临床试验(Clinical Trials)：

NCCN认為(wèi)任何癌症患者都可(kě)以在临床试验中得到最佳治疗，因此特别鼓励患者参与临床试验。  寻找NCCN成员组：https://www.nccn.org/home/member-institutions

5.NCCN对证据和共识分(fēn)类( NCCN Categories of Evidence and Consensus)：

推荐均為(wèi)2A类，除非另有(yǒu)说明，请参见下表：

6.NCCN首选分(fēn)类( NCCN Categories of Preference)：

所有(yǒu)建议均视為(wèi)合理(lǐ)，请参见下表：